APO Research
Talk to an analyst

APO RESEARCH · REPORT

ADCC Enhanced Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global ADCC Enhanced Antibody Market Outlook and Growth Opportunities 2026

30 December 2025198 pages

Choose your research edition.

Industry ResearchADCC Enhanced Antibody Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal ADCC Enhanced Antibody Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal ADCC Enhanced Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ADCC Enhanced Antibody Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal ADCC Enhanced Antibody Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global ADCC Enhanced Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the ADCC Enhanced Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the ADCC Enhanced Antibody market include C.H. Boehringer Sohn, Daiichi Sankyo, Jazz Pharmaceuticals, MacroGenics, Merus NV, Novartis AG, Puma Biotechnology, Roche Holding AG and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global ADCC Enhanced Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of ADCC Enhanced Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents ADCC Enhanced Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the ADCC Enhanced Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

ADCC Enhanced Antibody Segment by Company

C.H. Boehringer Sohn

Daiichi Sankyo

Jazz Pharmaceuticals

MacroGenics

Merus NV

Novartis AG

Puma Biotechnology

Roche Holding AG

Takeda Pharmaceutical

Dizal (Jiangsu) Pharmaceutical

Hengrui Medicine

Pfizer

RemeGen Biopharma

Sansheng Guojian

ADCC Enhanced Antibody Segment by Type

Fc Fusion Protein

Monospecific Antibody

Polyspecific Antibody

Antibody Fusion Protein

ADCC Enhanced Antibody Segment by Application

Hospital

Clinic

Others

ADCC Enhanced Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global ADCC Enhanced Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions ADCC Enhanced Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify ADCC Enhanced Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze ADCC Enhanced Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADCC Enhanced Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ADCC Enhanced Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADCC Enhanced Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the ADCC Enhanced Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ADCC Enhanced Antibody industry.

Chapter 3: Detailed analysis of ADCC Enhanced Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of ADCC Enhanced Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of ADCC Enhanced Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. ADCC Enhanced Antibody Industry Trends Table 2. ADCC Enhanced Antibody Industry Drivers Table 3. ADCC Enhanced Antibody Industry Opportunities and Challenges Table 4. ADCC Enhanced Antibody Industry Restraints Table 5. Global ADCC Enhanced Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global ADCC Enhanced Antibody Revenue Share by Company (2021-2026) Table 7. Global ADCC Enhanced Antibody Sales Volume by Company (Units) & (2021-2026) Table 8. Global ADCC Enhanced Antibody Sales Volume Share by Company (2021-2026) Table 9. Global ADCC Enhanced Antibody Average Price (K US$/Unit) of Company (2021-2026) Table 10. Global ADCC Enhanced Antibody Company Ranking, (2024-2026) & (USD Million) Table 11. Global ADCC Enhanced Antibody Key Company Manufacturing Base & Headquarters Table 12. Global ADCC Enhanced Antibody Company, Product Type & Application Table 13. Global ADCC Enhanced Antibody Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global ADCC Enhanced Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Fc Fusion Protein Table 18. Significant Companies of Monospecific Antibody Table 19. Significant Companies of Polyspecific Antibody Table 20. Significant Companies of Antibody Fusion Protein Table 21. Global ADCC Enhanced Antibody Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 22. Global ADCC Enhanced Antibody Sales Volume by Type (2021-2026) & (Units) Table 23. Global ADCC Enhanced Antibody Sales Volume by Type (2027-2032) & (Units) Table 24. Global ADCC Enhanced Antibody Sales Volume Share by Type (2021-2026) Table 25. Global ADCC Enhanced Antibody Sales Volume Share by Type (2027-2032) Table 26. Global ADCC Enhanced Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global ADCC Enhanced Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global ADCC Enhanced Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global ADCC Enhanced Antibody Sales Value Share by Type (2021-2026) Table 30. Global ADCC Enhanced Antibody Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global ADCC Enhanced Antibody Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 35. Global ADCC Enhanced Antibody Sales Volume by Application (2021-2026) & (Units) Table 36. Global ADCC Enhanced Antibody Sales Volume by Application (2027-2032) & (Units) Table 37. Global ADCC Enhanced Antibody Sales Volume Share by Application (2021-2026) Table 38. Global ADCC Enhanced Antibody Sales Volume Share by Application (2027-2032) Table 39. Global ADCC Enhanced Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global ADCC Enhanced Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global ADCC Enhanced Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global ADCC Enhanced Antibody Sales Value Share by Application (2021-2026) Table 43. Global ADCC Enhanced Antibody Sales Value Share by Application (2027-2032) Table 44. Global ADCC Enhanced Antibody Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 45. Global ADCC Enhanced Antibody Sales by Region (2021-2026) & (Units) Table 46. Global ADCC Enhanced Antibody Sales Market Share by Region (2021-2026) Table 47. Global ADCC Enhanced Antibody Sales by Region (2027-2032) & (Units) Table 48. Global ADCC Enhanced Antibody Sales Market Share by Region (2027-2032) Table 49. Global ADCC Enhanced Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global ADCC Enhanced Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global ADCC Enhanced Antibody Sales Value Share by Region (2021-2026) Table 52. Global ADCC Enhanced Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global ADCC Enhanced Antibody Sales Value Share by Region (2027-2032) Table 54. Global ADCC Enhanced Antibody Market Average Price (K US$/Unit) by Region (2021-2026) Table 55. Global ADCC Enhanced Antibody Market Average Price (K US$/Unit) by Region (2027-2032) Table 56. Global ADCC Enhanced Antibody Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 57. Global ADCC Enhanced Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global ADCC Enhanced Antibody Sales by Country (2021-2026) & (Units) Table 59. Global ADCC Enhanced Antibody Sales Market Share by Country (2021-2026) Table 60. Global ADCC Enhanced Antibody Sales by Country (2027-2032) & (Units) Table 61. Global ADCC Enhanced Antibody Sales Market Share by Country (2027-2032) Table 62. Global ADCC Enhanced Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global ADCC Enhanced Antibody Sales Value Market Share by Country (2021-2026) Table 64. Global ADCC Enhanced Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global ADCC Enhanced Antibody Sales Value Market Share by Country (2027-2032) Table 66. C.H. Boehringer Sohn Company Information Table 67. C.H. Boehringer Sohn Business Overview Table 68. C.H. Boehringer Sohn ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 69. C.H. Boehringer Sohn ADCC Enhanced Antibody Product Portfolio Table 70. C.H. Boehringer Sohn Recent Development Table 71. Daiichi Sankyo Company Information Table 72. Daiichi Sankyo Business Overview Table 73. Daiichi Sankyo ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 74. Daiichi Sankyo ADCC Enhanced Antibody Product Portfolio Table 75. Daiichi Sankyo Recent Development Table 76. Jazz Pharmaceuticals Company Information Table 77. Jazz Pharmaceuticals Business Overview Table 78. Jazz Pharmaceuticals ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 79. Jazz Pharmaceuticals ADCC Enhanced Antibody Product Portfolio Table 80. Jazz Pharmaceuticals Recent Development Table 81. MacroGenics Company Information Table 82. MacroGenics Business Overview Table 83. MacroGenics ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 84. MacroGenics ADCC Enhanced Antibody Product Portfolio Table 85. MacroGenics Recent Development Table 86. Merus NV Company Information Table 87. Merus NV Business Overview Table 88. Merus NV ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 89. Merus NV ADCC Enhanced Antibody Product Portfolio Table 90. Merus NV Recent Development Table 91. Novartis AG Company Information Table 92. Novartis AG Business Overview Table 93. Novartis AG ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 94. Novartis AG ADCC Enhanced Antibody Product Portfolio Table 95. Novartis AG Recent Development Table 96. Puma Biotechnology Company Information Table 97. Puma Biotechnology Business Overview Table 98. Puma Biotechnology ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 99. Puma Biotechnology ADCC Enhanced Antibody Product Portfolio Table 100. Puma Biotechnology Recent Development Table 101. Roche Holding AG Company Information Table 102. Roche Holding AG Business Overview Table 103. Roche Holding AG ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 104. Roche Holding AG ADCC Enhanced Antibody Product Portfolio Table 105. Roche Holding AG Recent Development Table 106. Takeda Pharmaceutical Company Information Table 107. Takeda Pharmaceutical Business Overview Table 108. Takeda Pharmaceutical ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 109. Takeda Pharmaceutical ADCC Enhanced Antibody Product Portfolio Table 110. Takeda Pharmaceutical Recent Development Table 111. Dizal (Jiangsu) Pharmaceutical Company Information Table 112. Dizal (Jiangsu) Pharmaceutical Business Overview Table 113. Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 114. Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Product Portfolio Table 115. Dizal (Jiangsu) Pharmaceutical Recent Development Table 116. Hengrui Medicine Company Information Table 117. Hengrui Medicine Business Overview Table 118. Hengrui Medicine ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 119. Hengrui Medicine ADCC Enhanced Antibody Product Portfolio Table 120. Hengrui Medicine Recent Development Table 121. Pfizer Company Information Table 122. Pfizer Business Overview Table 123. Pfizer ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 124. Pfizer ADCC Enhanced Antibody Product Portfolio Table 125. Pfizer Recent Development Table 126. RemeGen Biopharma Company Information Table 127. RemeGen Biopharma Business Overview Table 128. RemeGen Biopharma ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 129. RemeGen Biopharma ADCC Enhanced Antibody Product Portfolio Table 130. RemeGen Biopharma Recent Development Table 131. Sansheng Guojian Company Information Table 132. Sansheng Guojian Business Overview Table 133. Sansheng Guojian ADCC Enhanced Antibody Sales (Units), Value (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026) Table 134. Sansheng Guojian ADCC Enhanced Antibody Product Portfolio Table 135. Sansheng Guojian Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. ADCC Enhanced Antibody Distributors List Table 139. ADCC Enhanced Antibody Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. ADCC Enhanced Antibody Product Image Figure 2. Global ADCC Enhanced Antibody Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ADCC Enhanced Antibody Sales Value (2021-2032) & (US$ Million) Figure 4. Global ADCC Enhanced Antibody Sales (2021-2032) & (Units) Figure 5. Global ADCC Enhanced Antibody Sales Average Price (K US$/Unit) & (2021-2032) Figure 6. Global ADCC Enhanced Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Fc Fusion Protein Image Figure 10. Monospecific Antibody Image Figure 11. Polyspecific Antibody Image Figure 12. Antibody Fusion Protein Image Figure 13. Global ADCC Enhanced Antibody Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 14. Global ADCC Enhanced Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global ADCC Enhanced Antibody Sales Volume Share by Type (2021-2032) Figure 16. Global ADCC Enhanced Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global ADCC Enhanced Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global ADCC Enhanced Antibody Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global ADCC Enhanced Antibody Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 23. Global ADCC Enhanced Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global ADCC Enhanced Antibody Sales Volume Share by Application (2021-2032) Figure 25. Global ADCC Enhanced Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global ADCC Enhanced Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global ADCC Enhanced Antibody Sales Value Share by Application (2021-2032) Figure 28. Global ADCC Enhanced Antibody Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 29. Global ADCC Enhanced Antibody Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global ADCC Enhanced Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global ADCC Enhanced Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America ADCC Enhanced Antibody Sales Value (2021-2032) & (US$ Million) Figure 33. North America ADCC Enhanced Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe ADCC Enhanced Antibody Sales Value (2021-2032) & (US$ Million) Figure 35. Europe ADCC Enhanced Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific ADCC Enhanced Antibody Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific ADCC Enhanced Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America ADCC Enhanced Antibody Sales Value (2021-2032) & (US$ Million) Figure 39. South America ADCC Enhanced Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa ADCC Enhanced Antibody Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa ADCC Enhanced Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. ADCC Enhanced Antibody Value Chain Figure 127. Manufacturing Cost Structure Figure 128. ADCC Enhanced Antibody Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Fc Fusion Protein
  • Monospecific Antibody
  • Polyspecific Antibody
  • Antibody Fusion Protein
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • C.H. Boehringer Sohn
  • Daiichi Sankyo
  • Jazz Pharmaceuticals
  • MacroGenics
  • Merus NV
  • Novartis AG
  • Puma Biotechnology
  • Roche Holding AG
  • Takeda Pharmaceutical
  • Dizal (Jiangsu) Pharmaceutical
  • Hengrui Medicine
  • Pfizer
  • RemeGen Biopharma
  • Sansheng Guojian

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global ADCC Enhanced Antibody Sales Value (2021-2032)
  4. 1.2.2 Global ADCC Enhanced Antibody Sales Volume (2021-2032)
  5. 1.2.3 Global ADCC Enhanced Antibody Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 ADCC Enhanced Antibody Market Dynamics
  1. 2.1 ADCC Enhanced Antibody Industry Trends
  2. 2.2 ADCC Enhanced Antibody Industry Drivers
  3. 2.3 ADCC Enhanced Antibody Industry Opportunities and Challenges
  4. 2.4 ADCC Enhanced Antibody Industry Restraints
3 ADCC Enhanced Antibody Market by Company
  1. 3.1 Global ADCC Enhanced Antibody Company Revenue Ranking in 2025
  2. 3.2 Global ADCC Enhanced Antibody Revenue by Company (2021-2026)
  3. 3.3 Global ADCC Enhanced Antibody Sales Volume by Company (2021-2026)
  4. 3.4 Global ADCC Enhanced Antibody Average Price by Company (2021-2026)
  5. 3.5 Global ADCC Enhanced Antibody Company Ranking (2024-2026)
  6. 3.6 Global ADCC Enhanced Antibody Company Manufacturing Base and Headquarters
  7. 3.7 Global ADCC Enhanced Antibody Company Product Type and Application
  8. 3.8 Global ADCC Enhanced Antibody Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global ADCC Enhanced Antibody Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 ADCC Enhanced Antibody Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 ADCC Enhanced Antibody Market by Type
  1. 4.1 ADCC Enhanced Antibody Type Introduction
  2. 4.1.1 Fc Fusion Protein
  3. 4.1.2 Monospecific Antibody
  4. 4.1.3 Polyspecific Antibody
  5. 4.1.4 Antibody Fusion Protein
  6. 4.2 Global ADCC Enhanced Antibody Sales Volume by Type
  7. 4.2.1 Global ADCC Enhanced Antibody Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global ADCC Enhanced Antibody Sales Volume by Type (2021-2032)
  9. 4.2.3 Global ADCC Enhanced Antibody Sales Volume Share by Type (2021-2032)
  10. 4.3 Global ADCC Enhanced Antibody Sales Value by Type
  11. 4.3.1 Global ADCC Enhanced Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global ADCC Enhanced Antibody Sales Value by Type (2021-2032)
  13. 4.3.3 Global ADCC Enhanced Antibody Sales Value Share by Type (2021-2032)
5 ADCC Enhanced Antibody Market by Application
  1. 5.1 ADCC Enhanced Antibody Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global ADCC Enhanced Antibody Sales Volume by Application
  6. 5.2.1 Global ADCC Enhanced Antibody Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global ADCC Enhanced Antibody Sales Volume by Application (2021-2032)
  8. 5.2.3 Global ADCC Enhanced Antibody Sales Volume Share by Application (2021-2032)
  9. 5.3 Global ADCC Enhanced Antibody Sales Value by Application
  10. 5.3.1 Global ADCC Enhanced Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global ADCC Enhanced Antibody Sales Value by Application (2021-2032)
  12. 5.3.3 Global ADCC Enhanced Antibody Sales Value Share by Application (2021-2032)
6 ADCC Enhanced Antibody Regional Sales and Value Analysis
  1. 6.1 Global ADCC Enhanced Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global ADCC Enhanced Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global ADCC Enhanced Antibody Sales by Region: 2021-2026
  4. 6.2.2 Global ADCC Enhanced Antibody Sales by Region (2027-2032)
  5. 6.3 Global ADCC Enhanced Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global ADCC Enhanced Antibody Sales Value by Region (2021-2032)
  7. 6.4.1 Global ADCC Enhanced Antibody Sales Value by Region: 2021-2026
  8. 6.4.2 Global ADCC Enhanced Antibody Sales Value by Region (2027-2032)
  9. 6.5 Global ADCC Enhanced Antibody Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America ADCC Enhanced Antibody Sales Value (2021-2032)
  12. 6.6.2 North America ADCC Enhanced Antibody Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe ADCC Enhanced Antibody Sales Value (2021-2032)
  15. 6.7.2 Europe ADCC Enhanced Antibody Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific ADCC Enhanced Antibody Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific ADCC Enhanced Antibody Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America ADCC Enhanced Antibody Sales Value (2021-2032)
  21. 6.9.2 South America ADCC Enhanced Antibody Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa ADCC Enhanced Antibody Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa ADCC Enhanced Antibody Sales Value Share by Country, 2025 VS 2032
7 ADCC Enhanced Antibody Country-level Sales and Value Analysis
  1. 7.1 Global ADCC Enhanced Antibody Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global ADCC Enhanced Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global ADCC Enhanced Antibody Sales by Country (2021-2032)
  4. 7.3.1 Global ADCC Enhanced Antibody Sales by Country (2021-2026)
  5. 7.3.2 Global ADCC Enhanced Antibody Sales by Country (2027-2032)
  6. 7.4 Global ADCC Enhanced Antibody Sales Value by Country (2021-2032)
  7. 7.4.1 Global ADCC Enhanced Antibody Sales Value by Country (2021-2026)
  8. 7.4.2 Global ADCC Enhanced Antibody Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt ADCC Enhanced Antibody Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt ADCC Enhanced Antibody Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt ADCC Enhanced Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 C.H. Boehringer Sohn
  2. 8.1.1 C.H. Boehringer Sohn Company Information
  3. 8.1.2 C.H. Boehringer Sohn Business Overview
  4. 8.1.3 C.H. Boehringer Sohn ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 C.H. Boehringer Sohn ADCC Enhanced Antibody Product Portfolio
  6. 8.1.5 C.H. Boehringer Sohn Recent Developments
  7. 8.2 Daiichi Sankyo
  8. 8.2.1 Daiichi Sankyo Company Information
  9. 8.2.2 Daiichi Sankyo Business Overview
  10. 8.2.3 Daiichi Sankyo ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Daiichi Sankyo ADCC Enhanced Antibody Product Portfolio
  12. 8.2.5 Daiichi Sankyo Recent Developments
  13. 8.3 Jazz Pharmaceuticals
  14. 8.3.1 Jazz Pharmaceuticals Company Information
  15. 8.3.2 Jazz Pharmaceuticals Business Overview
  16. 8.3.3 Jazz Pharmaceuticals ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jazz Pharmaceuticals ADCC Enhanced Antibody Product Portfolio
  18. 8.3.5 Jazz Pharmaceuticals Recent Developments
  19. 8.4 MacroGenics
  20. 8.4.1 MacroGenics Company Information
  21. 8.4.2 MacroGenics Business Overview
  22. 8.4.3 MacroGenics ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MacroGenics ADCC Enhanced Antibody Product Portfolio
  24. 8.4.5 MacroGenics Recent Developments
  25. 8.5 Merus NV
  26. 8.5.1 Merus NV Company Information
  27. 8.5.2 Merus NV Business Overview
  28. 8.5.3 Merus NV ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merus NV ADCC Enhanced Antibody Product Portfolio
  30. 8.5.5 Merus NV Recent Developments
  31. 8.6 Novartis AG
  32. 8.6.1 Novartis AG Company Information
  33. 8.6.2 Novartis AG Business Overview
  34. 8.6.3 Novartis AG ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis AG ADCC Enhanced Antibody Product Portfolio
  36. 8.6.5 Novartis AG Recent Developments
  37. 8.7 Puma Biotechnology
  38. 8.7.1 Puma Biotechnology Company Information
  39. 8.7.2 Puma Biotechnology Business Overview
  40. 8.7.3 Puma Biotechnology ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Puma Biotechnology ADCC Enhanced Antibody Product Portfolio
  42. 8.7.5 Puma Biotechnology Recent Developments
  43. 8.8 Roche Holding AG
  44. 8.8.1 Roche Holding AG Company Information
  45. 8.8.2 Roche Holding AG Business Overview
  46. 8.8.3 Roche Holding AG ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Roche Holding AG ADCC Enhanced Antibody Product Portfolio
  48. 8.8.5 Roche Holding AG Recent Developments
  49. 8.9 Takeda Pharmaceutical
  50. 8.9.1 Takeda Pharmaceutical Company Information
  51. 8.9.2 Takeda Pharmaceutical Business Overview
  52. 8.9.3 Takeda Pharmaceutical ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Pharmaceutical ADCC Enhanced Antibody Product Portfolio
  54. 8.9.5 Takeda Pharmaceutical Recent Developments
  55. 8.10 Dizal (Jiangsu) Pharmaceutical
  56. 8.10.1 Dizal (Jiangsu) Pharmaceutical Company Information
  57. 8.10.2 Dizal (Jiangsu) Pharmaceutical Business Overview
  58. 8.10.3 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Product Portfolio
  60. 8.10.5 Dizal (Jiangsu) Pharmaceutical Recent Developments
  61. 8.11 Hengrui Medicine
  62. 8.11.1 Hengrui Medicine Company Information
  63. 8.11.2 Hengrui Medicine Business Overview
  64. 8.11.3 Hengrui Medicine ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hengrui Medicine ADCC Enhanced Antibody Product Portfolio
  66. 8.11.5 Hengrui Medicine Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer ADCC Enhanced Antibody Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 RemeGen Biopharma
  74. 8.13.1 RemeGen Biopharma Company Information
  75. 8.13.2 RemeGen Biopharma Business Overview
  76. 8.13.3 RemeGen Biopharma ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 RemeGen Biopharma ADCC Enhanced Antibody Product Portfolio
  78. 8.13.5 RemeGen Biopharma Recent Developments
  79. 8.14 Sansheng Guojian
  80. 8.14.1 Sansheng Guojian Company Information
  81. 8.14.2 Sansheng Guojian Business Overview
  82. 8.14.3 Sansheng Guojian ADCC Enhanced Antibody Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sansheng Guojian ADCC Enhanced Antibody Product Portfolio
  84. 8.14.5 Sansheng Guojian Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 ADCC Enhanced Antibody Value Chain Analysis
  2. 9.1.1 ADCC Enhanced Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 ADCC Enhanced Antibody Sales Mode & Process
  6. 9.2 ADCC Enhanced Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 ADCC Enhanced Antibody Distributors
  9. 9.2.3 ADCC Enhanced Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst